Business description not available.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 75M | 75M | 59M | 64M | 60M | 45M |
| Net Income | 0 | 0 | 20M | 26M | 0 | 14M |
| EPS | $1,624.49 | $1,624.49 | $1.13 | $1.49 | $1,296.18 | $0.81 |
| Free Cash Flow | 27M | 27M | 16M | 19M | 19M | 15M |
| ROIC | 0.0% | 58.0% | 42.3% | 81.3% | - | 71.8% |
| Gross Margin | 93.9% | 93.9% | 90.2% | 93.0% | 90.0% | 90.1% |
| Debt/Equity | 0.00 | 0.01 | 0.02 | 0.01 | 0.02 | 0.04 |
| Dividends/Share | $0.00 | $0.00 | $0.87 | $0.00 | $0.00 | $0.24 |
| Operating Income | 36M | 36M | 24M | 34M | 29M | 18M |
| Operating Margin | 47.7% | 47.7% | 41.5% | 52.1% | 47.5% | 41.3% |
| ROE | 0.0% | - | 22.8% | 33.5% | - | 33.3% |
| Shares Outstanding | 0M | 0M | 17M | 17M | 0M | 17M |
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 45M | 60M | 64M | 59M | 75M | 75M |
| Gross Margin | 90.1% | 90.0% | 93.0% | 90.2% | 93.9% | 93.9% |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | 18M | 29M | 34M | 24M | 36M | 36M |
| Op. Margin | 41.3% | 47.5% | 52.1% | 41.5% | 47.7% | 47.7% |
| Net Income | 14M | 0 | 26M | 20M | 0 | 0 |
| Net Margin | 31.4% | N/A | 40.4% | 33.5% | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||
| ROIC | 71.8% | N/A | 81.3% | 42.3% | 58.0% | 0.0% |
| ROE | 33.3% | N/A | 33.5% | 22.8% | N/A | 0.0% |
| ROA | 23.8% | N/A | 30.1% | 18.7% | N/A | 0.0% |
| Cash Flow | ||||||
| Op. Cash Flow | 17M | 25M | 22M | 19M | 31M | 31M |
| Free Cash Flow | 15M | 19M | 19M | 16M | 27M | 27M |
| Owner Earnings | 14M | 22M | 19M | 16M | 28M | 28M |
| CapEx | 1.8M | 5.5M | 3.1M | 3.0M | 4.5M | 4.5M |
| Maint. CapEx | 3.1M | 2.8M | 3.0M | 2.5M | 3.3M | 3.3M |
| Growth CapEx | 0 | 2.7M | 104K | 541K | 1.3M | 1.3M |
| D&A | 3.1M | 2.8M | 3.0M | 2.5M | 3.3M | 3.3M |
| CapEx/OCF | 10.4% | 22.1% | 13.7% | 16.2% | 14.4% | 14.4% |
| Capital Allocation | ||||||
| Dividends Paid | 4.1M | 9.9M | 0 | 15M | 11M | 11M |
| Dividend Yield | 0.2% | N/A | N/A | 1.5% | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Stock-Based Comp | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt Repayment | 0 | 0 | 0 | 46K | 740K | 740K |
| Balance Sheet | ||||||
| Net Debt | -22M | -28M | -45M | -42M | -51M | -52M |
| Cash & Equiv. | 24M | 30M | 46M | 43M | 52M | 52M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | 0.04 | 0.02 | 0.01 | 0.02 | 0.01 | 0.00 |
| Interest Coverage | 27.6 | 133.6 | 84.9 | 132.0 | 98.5 | 98.5 |
| Equity | 42M | 51M | 78M | 87M | 99M | 99M |
| Total Assets | 59M | 79M | 86M | 106M | 119M | 119M |
| Total Liabilities | 14M | 14M | 14M | 19M | 20M | 20M |
| Intangibles | 0 | 0 | 0 | 20M | 27M | 27M |
| Retained Earnings | 0 | 0 | 0 | 0 | 0 | 0 |
| Working Capital | 26M | 43M | 48M | 53M | 55M | 55M |
| Current Assets | 38M | 56M | 61M | 71M | 73M | 73M |
| Current Liabilities | 12M | 13M | 13M | 18M | 19M | 19M |
| Per Share Data | ||||||
| EPS | 0.81 | 1,296.18 | 1.49 | 1.13 | 1,624.49 | 1,624.49 |
| Owner EPS | 0.81 | N/A | 1.12 | 0.93 | N/A | N/A |
| Book Value | 2.42 | 0.00 | 4.46 | 4.98 | 0.00 | 0.00 |
| Cash Flow/Share | 0.98 | 0.00 | 1.67 | 1.28 | 0.00 | 0.00 |
| Dividends/Share | 0.24 | 0.00 | 0.00 | 0.87 | 0.00 | 0.00 |
| Shares Out. | 17.4M | 0.0M | 17.4M | 17.4M | 0.0M | 0.0M |
| Valuation | ||||||
| P/E Ratio | 147.1 | 0.1 | 38.4 | 62.5 | 0.1 | 0.2 |
| P/FCF | 134.5 | N/A | 51.6 | 78.8 | N/A | N/A |
| EV/EBIT | 110.9 | -1.0 | 28.4 | 48.7 | -1.4 | -1.4 |
| Price/Book | 49.1 | N/A | 12.9 | 14.2 | N/A | N/A |
| Price/Sales | 46.2 | N/A | 15.5 | 20.9 | N/A | N/A |
| FCF Yield | 0.7% | N/A | 1.9% | 1.3% | N/A | N/A |
| Market Cap | 2.1B | 0 | 999M | 1.2B | 0 | 0 |
| Avg. Price | 124.80 | 107.27 | 63.02 | 58.39 | 88.93 | 303.40 |
| Year-End Price | 118.60 | 108.02 | 57.45 | 70.88 | 107.50 | 303.40 |
ChemoMetec A/S passes 5 of 9 quality checks, suggesting mixed fundamentals.
ChemoMetec A/S trades at 267.5x trailing earnings, compared to its 15-year median P/E of 19.3x, suggesting it is currently Expensive relative to its historical range. On a free-cash-flow basis, the stock trades at 337.4x vs a median of 65.2x. The company's 5-year average ROIC is 63.3% with a gross margin of 91.5%. At current prices, the estimated annualized return to fair value is +2.0%.
ChemoMetec A/S (CHEMM-CO) has a current P/E ratio of 267.5, compared to its historical median P/E of 19.3. The stock is currently considered Expensive based on its historical valuation range.
ChemoMetec A/S (CHEMM-CO) has a 5-year average return on invested capital (ROIC) of 63.3%. This indicates strong capital allocation and a potential competitive advantage.
ChemoMetec A/S (CHEMM-CO) does not currently pay a regular dividend.
Based on historical P/E analysis, ChemoMetec A/S (CHEMM-CO) appears expensive. The current P/E of 267.5 is 1289% above its historical median of 19.3. The estimated fair value CAGR (P/E method) is 9.1%.
ChemoMetec A/S (CHEMM-CO) reported annual revenue of $75 million in its most recent fiscal year, based on SEC EDGAR filings.
ChemoMetec A/S (CHEMM-CO) generated $27 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
ChemoMetec A/S (CHEMM-CO) has a debt-to-equity ratio of 0.01. This indicates a conservatively financed balance sheet.
ChemoMetec A/S (CHEMM-CO) reported earnings per share (EPS) of $1624.49 in its most recent fiscal year.
ChemoMetec A/S (CHEMM-CO) has a 5-year average gross margin of 91.5%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 5 years of financial data for ChemoMetec A/S (CHEMM-CO), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.